Ipamorelin peptides CJC-1295 injection is a research-only stack studied for growth hormone release. Learn how it works, dosing, and safety basics.
The ipamorelin peptides cjc-1295 injection combination is a research-only pairing studied for its ability to trigger growth hormone release from the pituitary gland. Ipamorelin targets ghrelin receptors while CJC-1295 targets GHRH receptors, and the two pathways appear to reinforce each other in laboratory and animal models. Neither compound is FDA-approved for human use in the United States.
What Are Ipamorelin and CJC-1295?
Ipamorelin is a synthetic pentapeptide and a selective growth hormone secretagogue. It binds the ghrelin receptor, also called GHS-R1a.
CJC-1295 is a modified growth hormone-releasing hormone (GHRH) analog. It is sold in two research forms that behave very differently:
- CJC-1295 with DAC — the drug affinity complex binds albumin in the bloodstream and extends the half-life to roughly a week.
- CJC-1295 without DAC — also called mod GRF 1-29, a short-acting form with a half-life measured in minutes.
Both peptides ship as lyophilized powder. Researchers reconstitute them with bacteriostatic water before use, and both are labeled for research use only.
How the Two Peptides Work Together
Growth hormone release is controlled by several receptor systems in the pituitary, and GHRH plus ghrelin signaling are two of the main ones.
Because ipamorelin and CJC-1295 act on different receptors, combining them is often described as pulling two levers at once. Preclinical work suggests the effect on GH pulses may be larger than either peptide produces alone.
Ipamorelin is frequently called a "clean" secretagogue in animal studies because it raises cortisol, prolactin, and appetite far less than older compounds such as GHRP-6.
That selectivity helps explain the growing importance of peptides in endocrine research, even though human clinical data remain thin.
Ipamorelin vs. CJC-1295 at a Glance
| Feature | Ipamorelin | CJC-1295 |
|---|---|---|
| Peptide class | Synthetic pentapeptide | Modified GHRH analog |
| Primary receptor | Ghrelin receptor (GHS-R1a) | GHRH receptor |
| Half-life | Minutes | ~6–8 days with DAC; ~30 minutes without DAC |
| Cortisol and prolactin effect | Minimal in animal models | Acts upstream of the pituitary |
| FDA status | Not approved for human use | Not approved for human use |
Dosage and Protocol in Research Settings
Most cjc-1295 ipamorelin dosage figures circulating online come from rodent studies and self-reported logs, not from controlled human trials. Treat those numbers as research context, not medical guidance.
| Compound | Commonly cited research range | Frequency |
|---|---|---|
| Ipamorelin | 100–300 mcg | 1–3 times daily |
| CJC-1295 without DAC | 100–300 mcg | 1–3 times daily |
| CJC-1295 with DAC | 1–2 mg | Once weekly |
A typical cjc-1295 ipamorelin protocol in a laboratory setting pairs near-equal doses of both peptides in one injection. Timing is usually tied to natural GH pulses, such as before sleep or away from a meal.
Doses are drawn with insulin syringes and given subcutaneously in animal models. Human use is not approved, and anecdotal doses should never be copied.
How This Stack Compares With AOD-9604
AOD-9604 is a fragment of human growth hormone (HGH 176-191) studied for fat metabolism rather than GH release. When people search aod-9604 vs cjc-1295 ipamorelin, they are usually comparing two different research goals: fat pathways versus growth hormone secretion.
Because the mechanisms differ, some researchers examine cjc 1295 ipamorelin aod 9604 as three separate compounds rather than one blend.
| Compound | Primary research interest | Effect on GH and IGF-1 | Half-life |
|---|---|---|---|
| Ipamorelin | GH secretion | Increases GH pulses | Minutes |
| CJC-1295 without DAC | GHRH signaling | Increases GH pulses | ~30 minutes |
| CJC-1295 with DAC | Sustained GHRH signaling | Raises IGF-1 over days | ~6–8 days |
| AOD-9604 | Fat metabolism | Little to none | ~30 minutes |
AOD-9604 does not drive GH release the way a secretagogue does, so it is studied as a separate compound rather than as part of this stack.
What the Research Does and Doesn't Show
Most published data on these peptides come from animal models, cell cultures, and small short-term studies. Results in rodents do not automatically translate to humans.
No large randomized human trial shows that an ipamorelin and CJC-1295 injection improves body composition, recovery, or longevity. Claims of that kind are marketing, not evidence.
What the data do support is a measurable rise in GH and IGF-1 markers after combined GHRH and ghrelin-receptor stimulation. Whether that produces any health benefit remains unproven.
Safety, Legal Status, and Sourcing
Ipamorelin and CJC-1295 are not approved by the FDA for human use. In the US they are sold as research chemicals, and buying them for personal injection is not a legal therapeutic use.
- Reported research side effects include injection site irritation, headache, flushing, and shifts in blood sugar or IGF-1.
- Long-term human safety data for both peptides are essentially absent.
- Purity varies widely, and unverified powders may contain impurities or the wrong peptide entirely.
Reputable suppliers publish third-party certificates of analysis. Some vendors, such as imperium research peptides, share batch testing and purity results, but a COA does not make a research chemical safe or legal for human use.
Anyone with a hormone-sensitive condition, diabetes, or who is pregnant should avoid these compounds and speak with a licensed healthcare professional instead.
Frequently Asked Questions
Is the ipamorelin CJC-1295 injection FDA approved?
No. Ipamorelin and CJC-1295 are not FDA-approved for human use in the United States, and no prescription version of this combination exists. Both peptides are sold as research chemicals for laboratory study only, not for human injection.
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 with DAC binds albumin and stays active for roughly six to eight days, so it is usually studied as a once-weekly dose. CJC-1295 without DAC (mod GRF 1-29) has a half-life of about 30 minutes and is typically paired with ipamorelin for multiple daily pulses.
Can ipamorelin and CJC-1295 be mixed in the same syringe?
In research settings the two peptides are often drawn into the same syringe because they are compatible in bacteriostatic water. That does not make the combination approved or safe for human injection. Anyone considering peptide use should consult a licensed healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.